Correlation Between Molecular Partners and Cidara Therapeutics

Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Cidara Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Cidara Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molecular Partners AG and Cidara Therapeutics, you can compare the effects of market volatilities on Molecular Partners and Cidara Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Cidara Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Cidara Therapeutics.

Diversification Opportunities for Molecular Partners and Cidara Therapeutics

0.32

Correlation Coefficient

Molecular Partners  Cidara Therapeutics

Weak diversification

The 3 months correlation between Molecular and Cidara is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Cidara Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cidara Therapeutics and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Cidara Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cidara Therapeutics has no effect on the direction of Molecular Partners i.e., Molecular Partners and Cidara Therapeutics go up and down completely randomly.

Pair Corralation between Molecular Partners and Cidara Therapeutics

Given the investment horizon of 90 days Molecular Partners is expected to generate 3.52 times less return on investment than Cidara Therapeutics. In addition to that, Molecular Partners is 1.7 times more volatile than Cidara Therapeutics. It trades about 0.04 of its total potential returns per unit of risk. Cidara Therapeutics is currently generating about 0.23 per unit of volatility. If you would invest  1,159  in Cidara Therapeutics on September 2, 2024 and sell it today you would earn a total of  862.00  from holding Cidara Therapeutics or generate 74.37% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Molecular Partners AG  vs.  Cidara Therapeutics

Molecular Partners

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Molecular Partners displayed solid returns over the last few months and may actually be approaching a breakup point.

Cidara Therapeutics

Risk-Adjusted Performance

18 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Cidara Therapeutics are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Cidara Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Molecular Partners and Cidara Therapeutics

The main advantage of trading using opposite Molecular Partners and Cidara Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Cidara Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cidara Therapeutics will offset losses from the drop in Cidara Therapeutics' long position.

The idea behind Molecular Partners AG and Cidara Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.